Mucosal Atomization Device Market – Product Type (Nasal Atomization, Fiber Optic Atomization, Laryngo Tracheal Atomization, Bottle Atomizers), Technology (Gas Propelled Atomization, Electrical Atomization), End User – Global Forecast (2024 ­ 2032)

Mucosal atomization device industry size recorded over USD 712.3 million in 2023 and is expected to depict 7.4% CAGR from 2024 to 2032, owing to the rising prevalence of respiratory illnesses, and the expanding adoption of intranasal drug delivery systems

The nasal atomization devices segment in the market accumulated 36.6% share in 2023 and is estimated to grow at substantial CAGR between 2024 and 2032, on account of the surging incidences of respiratory illness.

North America mucosal atomization device industry is projected to be worth USD 498.9 million by 2032, due to the robust presence of advanced healthcare facilities, high demand for non-invasive drug delivery solutions, and the increasing cases of respiratory illness.

Becton, Dickinson, and Co., BTME Group Ltd. (Medtree), BVM Meditech Pvt. Ltd., Cook Medical, Inc., DeVilbiss Healthcare LLC, Intersurgical Ltd., Kurve Therapeutics, Life-Assist Inc., Medica Holdings, LLC, Medspray, Pulmodyne, Inc., and Teleflex Inc. are some of the leading mucosal atomization device companies worldwide.